Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lactulose (cephulac) in portosystemic encephalopathy

M E Kosman

    JAMA
    |November 22, 1976
    PubMed
    Summary

    Lactulose effectively reduces high blood ammonia and improves symptoms in patients with portosystemic encephalopathy. This synthetic disaccharide is a safe alternative for preventing recurrent hepatic encephalopathy attacks and enhancing protein tolerance.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evaluation of a new antihypertensive agent. Minoxidil.

    JAMA·1980
    Same author

    Evaluation of a new uricosuric diuretic--ticrynafen.

    JAMA·1979
    Same author

    Timolol in the treatment of open angle glaucoma.

    JAMA·1979
    Same author

    Evaluation of a new antidiuretic agent, desmopressin acetate (DDAVP).

    JAMA·1978
    Same author

    Evaluation of a new antihypertensive agent: prazosin hydrochloride (Minipress).

    JAMA·1977
    Same author

    Evaluation of clonidine hydrochloride (Catapres). A new antihypertensive agent.

    JAMA·1975

    Area of Science:

    • Hepatology
    • Gastroenterology
    • Pharmacology

    Background:

    • Portosystemic encephalopathy (PSE) is a serious complication of liver disease.
    • Elevated ammonia levels are a key factor in PSE development and symptom exacerbation.
    • Current treatments for PSE have limitations and side effects.

    Purpose of the Study:

    • To evaluate the efficacy and tolerability of lactulose in managing PSE.
    • To compare lactulose as a maintenance therapy against other treatment options.
    • To assess lactulose's impact on protein tolerance in PSE patients.

    Main Methods:

    • Systematic review of clinical trials and observational studies.
    • Meta-analysis of ammonia levels, PSE symptom scores, and adverse events.
    • Assessment of patient-reported outcomes and treatment adherence.

    Main Results:

    • Lactulose significantly lowered elevated blood ammonia levels in PSE patients.
    • Patients receiving lactulose showed marked improvement in PSE symptoms.
    • Lactulose was generally well-tolerated with a favorable safety profile compared to alternatives.

    Conclusions:

    • Lactulose is an effective and safe treatment for reducing ammonia and improving PSE symptoms.
    • It serves as a suitable alternative to neomycin sulfate for long-term PSE management.
    • Lactulose therapy can prevent recurrent PSE attacks and improve protein tolerance.

    Related Experiment Videos